SpyGlass Pharma, Inc. (SGP)
SpyGlass Pharma will go public soon, but the exact IPO date is still unknown.
Stock Price: Pending
IPO price not available yet
Company Description
SpyGlass Pharma is a late-stage biopharmaceutical company dedicated to transforming the treatment paradigm for patients living with chronic eye conditions through long-acting, sustained drug delivery of approved medicines.
Our mission is to significantly improve the lives of patients with chronic eye conditions by developing durable drug delivery solutions that can empower patients and surgeons with confidence in long-term disease control and vision preservation.
SpyGlass Pharma, Inc.
| Country | United States |
| Founded | 2019 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 65 |
| CEO | Patrick Mooney |
Contact Details
Address: 27061 Aliso Creek Rd., Suite 100 Aliso Viejo, CA 92656 United States | |
| Phone | (949) 284-6904 |
| Website | spyglasspharma.com |
Stock Details
| Ticker Symbol | SGP |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 1778922 |
| Employer ID | 83-3044245 |
| SIC Code | 3841 |
Key Executives
| Name | Position |
|---|---|
| Patrick Mooney | Chief Executive Officer and Director |
| Malik Y. Kahook, M.D. | Co-founder, President, Chief Medical Officer, Executive Chair of the Board and Director |
| James Dennewill | Chief Operating Officer |
| Chetan Pujara, Ph.D. | Chief Research and Development Officer |
| Jean-Frédéric Viret, Ph.D. | Chief Financial Officer |
| Glenn Sussman | Co-founder and Chief Technology Advisor |
| Ali Behbahani, M.D. | Director |
| Michael Dybbs, Ph.D. | Director |
| Bilal Khan | Director |
| Kirk Nielsen | Director |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 16, 2026 | S-1 | General form for registration of securities under the Securities Act of 1933 |
| Dec 10, 2025 | DRS/A | [Amend] [Cover] Draft Registration Statement |
| Sep 26, 2025 | DRS | [Cover] Draft Registration Statement |
| Jun 5, 2025 | D | Notice of Exempt Offering of Securities |
| Jul 11, 2023 | D | Notice of Exempt Offering of Securities |
| Jan 5, 2021 | D | Notice of Exempt Offering of Securities |
| Jun 5, 2019 | D | Notice of Exempt Offering of Securities |